SSBP2 Antibody

What is SSBP2 and what is its molecular function?

SSBP2 (also known as SSDP2) is a 361 amino acid protein with a calculated molecular weight of 38 kDa that typically appears at 40 kDa in experimental conditions. It functions primarily by binding to single-stranded DNA, protecting it from degradation and facilitating proper DNA replication and repair processes . SSBP2 is predominantly localized in the nucleus where its presence is vital for maintaining genomic stability and regulating cell cycle progression . Mechanistically, SSBP2 stabilizes single-stranded DNA by preventing the formation of secondary structures, which is critical during DNA replication and repair processes .

What types of SSBP2 antibodies are available for research applications?

Several validated SSBP2 antibodies are available for research applications:

Which tissues normally express SSBP2 and how does this affect antibody validation?

SSBP2 expression shows marked tissue specificity. In normal liver, hepatocytes are negative for SSBP2, while nuclei of bile duct epithelium and sinusoidal endothelium show immunoreactivity . In bone marrow, SSBP2 expression is restricted to approximately 5% of all cells, primarily in hematopoietic stem and progenitor cell (HSPC) populations . Expression is higher in long-term and short-term HSPCs than in committed progenitor cells, suggesting repression during differentiation . This restricted expression pattern requires thorough validation using appropriate positive and negative controls when establishing antibody specificity.

What are the optimal conditions for using SSBP2 antibodies in immunohistochemistry?

For immunohistochemistry applications, heat-mediated antigen retrieval with citrate buffer (pH 6.0) is consistently recommended before commencing with IHC staining protocols . The Abcam antibody (ab177944) has been validated at 1/50 dilution for IHC-P applications . For tissue microarray studies, positive SSBP2 expression has been defined as more than 10% of tumor cells showing nuclear staining . When performing immunostaining, it's advisable to include known positive controls (such as bile duct epithelium or sinusoidal endothelium in liver sections) alongside experimental tissues to validate staining patterns .

How should SSBP2 antibodies be validated for Western blotting experiments?

For Western blotting, the expected molecular weight of SSBP2 is 38 kDa, though it is commonly observed at approximately 40 kDa . The Abcam antibody (ab177944) has been validated at 1/1000 dilution with confirmed reactivity in Jurkat, K562, and Raji cell lysates, as well as fetal heart tissue lysate . When validating a new SSBP2 antibody for Western blotting, researchers should include known positive controls such as these cell lines, and potentially a negative control using SSBP2 knockout or knockdown samples. Immunoblots developed with rabbit polyclonal antibodies to SSBP2 (1:10,000 dilution) have been successfully used in previous studies .

What is the recommended storage and handling procedure for SSBP2 antibodies?

SSBP2 antibodies should typically be stored at -20°C and remain stable for one year after shipment . For the Proteintech antibody (12528-1-AP), aliquoting is unnecessary for -20°C storage, and the smaller 20μl sizes contain 0.1% BSA . The storage buffer generally consists of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . When working with antibodies, avoid repeated freeze-thaw cycles by preparing appropriate working aliquots for routine use.

How can SSBP2 antibodies be used to study its role as a tumor suppressor?

SSBP2 has been identified as a tumor suppressor in multiple studies, showing silencing by promoter hypermethylation in hematologic malignancies, prostate cancer, esophageal squamous cell carcinoma, ovarian cancer, and gallbladder cancer . Researchers can use SSBP2 antibodies in immunohistochemistry to investigate expression patterns in tumor versus normal tissues. For instance, in hepatocellular carcinoma studies, SSBP2 was expressed in only 8.5% (16/189) of HCC samples compared to 0.6% (1/180) in adjacent non-neoplastic tissues . The semi-quantitative evaluation method (considering both staining intensity and proportion of stained cells) provides a standardized approach to score expression levels across tumor samples .

How do researchers reconcile contradictory findings about SSBP2 as both tumor suppressor and oncogene?

When investigating these contradictions, researchers should:

• Use multiple antibodies targeting different epitopes to confirm expression patterns

• Combine protein expression studies with genetic and epigenetic analyses

• Consider tissue-specific contexts and tumor microenvironment factors

• Examine SSBP2's interaction partners in different cellular contexts

What methodological approaches are recommended for studying SSBP2 expression in hematological malignancies?

For hematological malignancies, flow cytometry with SSBP2 antibodies is particularly valuable. Researchers can prepare single-cell suspensions from tissues (e.g., thymus or tumors) by dispersing organs between glass slides and passing through mesh filters . Cells should be briefly suspended in hypotonic buffer (0.15mM NH4Cl, 1mM KHCO3, and 300µM EDTA) to lyse red blood cells prior to staining .

Flow cytometry can be performed on instruments such as BD FACS-Caliber or FACS-Aria with data analysis using software like WinMDI 2.8 . When characterizing specific populations, combine SSBP2 staining with established markers such as CD4, CD8, CD3 for T cells or lineage markers (Ter119, Gr1, CD11b, CD3, CD4, CD8) with CD25 and CD44 for hematopoietic progenitors .

How can researchers study SSBP2's role in hematopoietic stem cell maintenance?

SSBP2 plays a crucial role in hematopoietic stem cell maintenance, with its expression being higher in long-term and short-term hematopoietic stem and progenitor cell (HSPC) populations than in committed progenitor cells . To study this role, researchers can employ the following methodological approaches:

• Isolate BM cells enriched for HSPC subpopulations and analyze SSBP2 transcript levels across different populations (Flt3−LSK, Flt3+LSK, LKs, Lin+)

• Use immunofluorescence staining of whole BM with anti-SSBP2 antibodies, with nuclear DNA counterstaining

• Conduct comparative studies between wild-type and Ssbp2-null mice to assess differences in hematopoietic activity across BM, spleen, and thymus

• Challenge mice with myeloablative drugs like 5-FU to evaluate SSBP2's role in stress responses and recovery

In previous studies, Ssbp2-null mice showed a 30-40% reduction in mononuclear populations across BM, spleen, and thymus, with significant differences in peripheral blood lymphocytes .

What are the challenges in detecting SSBP2 in bone marrow samples and how can they be overcome?

Detecting SSBP2 in bone marrow samples presents several challenges:

• Restricted expression pattern: SSBP2 is expressed in only approximately 5% of all cells in normal BM

• Differential expression across cell populations: Expression levels vary significantly between stem/progenitor and differentiated cells

• Need for multiple markers to identify specific subpopulations

To overcome these challenges:

• Use highly specific antibodies with validated nuclear staining patterns

• Employ multiparameter flow cytometry combining SSBP2 staining with stem cell markers (LSK, CD34, FLT3)

• Include proper controls, including Ssbp2-null samples if available, to validate antibody specificity

• For immunofluorescence approaches, optimize fixation conditions to preserve nuclear architecture while maintaining epitope accessibility

How can researchers address non-specific binding when using SSBP2 antibodies?

Non-specific binding can confound SSBP2 antibody experiments. To minimize this issue:

• Use antibodies purified through antigen affinity purification methods, such as the Proteintech antibody (12528-1-AP)

• Optimize blocking conditions using 5% BSA or normal serum from the species in which the secondary antibody was raised

• Include appropriate negative controls such as:

  • Primary antibody omission

  • Isotype controls (especially for monoclonal antibodies)

  • Tissue from Ssbp2-null models when available

• Titrate antibody concentrations to determine optimal working dilutions for each application

• For Western blotting, consider preabsorption of the antibody with recombinant SSBP2 protein as a specificity control

What are the best practices for quantifying SSBP2 expression in immunohistochemistry studies?

For accurate and reproducible quantification of SSBP2 expression in IHC studies:

• Use a semi-quantitative scoring system based on:

  • Staining intensity (0: negative, 1+: weak, 2+: moderate, 3+: strong)

  • Percentage of positive cells (0-100%)

  • Consider a combined score or defined threshold (e.g., >10% positive nuclei)

• Employ blinded evaluation by at least two independent pathologists to reduce bias

• Include positive controls (tissues known to express SSBP2, such as bile duct epithelium) and negative controls (hepatocytes in normal liver samples)

• For digital quantification, use validated image analysis software with appropriate nuclear detection algorithms

• Report both the methods of quantification and the distribution of scores to enable comparison across studies

In a ccRCC study, high SSBP2 expression was observed in 34.1% (59/173) of samples and low expression in 65.9% (114/173), with significant correlations to clinicopathological features .

How should researchers interpret variable molecular weights observed for SSBP2 in Western blots?

SSBP2 has a calculated molecular weight of 38 kDa but is commonly observed at approximately 40 kDa in experimental conditions . This discrepancy could be attributed to:

• Post-translational modifications affecting protein mobility

• Protein-specific structural features influencing SDS-PAGE migration

• Different isoforms or splice variants of SSBP2

To address this variability:

• Include positive controls with known SSBP2 expression (e.g., Jurkat, K562, or Raji cell lysates)

• Use protein ladders with close molecular weight markers in the 35-45 kDa range

• Consider running lysates from both wild-type and Ssbp2-null samples as controls when available

• If investigating specific isoforms, select antibodies that target epitopes present in all or specific isoforms as needed for the research question

How can SSBP2 antibodies be applied to study its role in genomic stability maintenance?

SSBP2's function in maintaining genomic stability through single-stranded DNA binding can be investigated using the following approaches:

• Chromatin immunoprecipitation (ChIP) using SSBP2 antibodies to identify genomic binding sites

• Co-immunoprecipitation to identify SSBP2 interaction partners in DNA repair complexes

• Immunofluorescence microscopy to detect SSBP2 localization to DNA damage sites after treatment with DNA-damaging agents

• Proximity ligation assays to visualize interactions between SSBP2 and DNA repair factors in situ

These approaches would benefit from highly specific monoclonal antibodies such as the Abcam (ab177944) or Santa Cruz (sc-166687) products .

What are the considerations for developing multiplex immunofluorescence panels including SSBP2?

Developing multiplex immunofluorescence panels that include SSBP2 requires careful consideration of:

• Antibody compatibility:

  • Species origin (avoid same-species antibodies unless directly conjugated)

  • Isotype differences for secondary antibody discrimination

  • Optimal working concentrations in multiplex versus single-staining conditions

• Antigen retrieval optimization:

  • Ensure all antibodies in the panel work with the same retrieval method (citrate buffer pH 6.0 is recommended for SSBP2)

• Fluorophore selection:

  • Choose fluorophores with minimal spectral overlap

  • Consider SSBP2's nuclear localization when selecting fluorophores (nuclear counterstains should be spectrally distinct)

• Controls:

  • Include single-stained controls for each antibody

  • Use fluorescence-minus-one (FMO) controls

  • Include known positive and negative tissues for SSBP2 expression

• Analysis approaches:

  • Employ appropriate image analysis software for nuclear and cytoplasmic signal quantification

  • Consider machine learning approaches for cell classification in complex tissues

What are the recommended practices for comparing SSBP2 expression across different tumor types?

Based on the literature, researchers should consider these methodological approaches when comparing SSBP2 expression across different tumor types:

• Standardize tissue processing and immunohistochemistry protocols:

  • Use consistent fixation methods (typically formalin-fixed, paraffin-embedded tissues)

  • Employ identical antigen retrieval conditions (citrate buffer, pH 6.0)

  • Use the same antibody clone and concentration across all samples

  • Process all samples in parallel to minimize batch effects

• Implement rigorous scoring criteria:

  • Use a semi-quantitative approach considering both intensity and percentage of positive cells

  • Apply consistent thresholds for categorizing expression levels (e.g., >10% nuclear positivity)

  • Involve multiple blinded evaluators

• Include appropriate controls:

  • Normal tissue counterparts for each tumor type

  • Known positive and negative tissues as technical controls

• Complement protein expression data:

  • Assess SSBP2 promoter methylation status across tumor types

  • Analyze mRNA expression levels using qRT-PCR or RNA-seq

  • Consider the broader context of SSBP2-interacting proteins in each tissue type